)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Rohto Pharmaceutical
Rohto Pharmaceutical (4527) investor relations material
Rohto Pharmaceutical Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary12 Nov, 2026
Executive summary
H1 FY2027 net sales reached a record ¥179,006 million, up 9.0% YoY; operating income rose 8.5% to ¥20,953 million.
Growth in Asia and Europe and improved Japan profitability offset U.S. weakness; ordinary income fell 11.2% and attributable profit fell 6.5%.
Financial highlights
H1 gross profit was ¥99,562 million and SG&A was ¥78,608 million; gross margin was 55.6% and operating margin 11.7%.
Ordinary income declined 11.2% to ¥21,845 million, reflecting the prior-year one-time dividend income comparison; attributable profit fell 6.5% to ¥16,498 million.
EBITDA rose 9.8% to ¥30,071 million; FX contributed ¥8.33bn to sales and ¥880m to operating income, while lower U.S. eye-drop shipments reduced sales by ¥670m YoY.
Comprehensive income rose to ¥23,678 million from ¥16,169 million, including ¥7,043 million of other comprehensive income; a ¥1,456 million gain on sale of investment securities was recorded.
Outlook and guidance
FY2027 forecast unchanged: sales ¥372.3bn (+8.3%), operating income ¥45.0bn (+9.4%), ordinary income ¥47.4bn (-1.2%), attributable profit ¥35.2bn (+2.8%) and EBITDA ¥63.7bn (+8.9%).
H1 progress against forecasts: sales 48.1%, operating income 46.6%, attributable profit 46.9% and EBITDA 47.2%; EPS forecast is ¥156.50.
Sales forecasts raised ¥500m for Japan and ¥400m for Asia, cut ¥1.2bn for the Americas and unchanged for Europe; operating-income forecasts raised ¥500m for Japan and ¥300m for Asia, cut ¥900m for the Americas and unchanged for Europe.
Forecast assumptions include USD/JPY 158 and CNY/JPY 23; risks include trade policy, geopolitical tensions, raw-material prices and FX trends.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Rohto Pharmaceutical
- Raised growth targets and global expansion drive innovation and shareholder value.4527
Investor presentation - Double-digit sales and profit growth in Q1 2026, with upwardly revised full-year forecasts.4527Q1 2027
- Record-high sales and profit growth driven by Asia and Europe, with higher dividends and robust outlook.4527Q4 2026
- Double-digit sales and profit growth led to upward forecasts and major acquisition integration.4527Q3 2026
- Strong sales growth, upward guidance, and OBAGI trademark acquisition drive record dividends.4527Q2 2026
- Sales up 19.9% year-over-year, with profit outlook and dividends raised on overseas growth.4527Q1 2026
- Sales rose but profits fell on higher costs; full-year outlook and expansion plans remain intact.4527Q2 2025
- Sales and profit forecasts raised as Asia growth and acquisitions drive outlook.4527Q1 2025
- Sales surged on overseas growth and acquisitions, but profits faced cost pressures.4527Q4 2025
Next Rohto Pharmaceutical earnings date
Q3 202712 Feb, 2027
Rohto Pharmaceutical
Next Rohto Pharmaceutical earnings date
Q3 202712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Rohto Pharmaceutical Co., Ltd. is a Japanese multinational corporation specializing in health and beauty care products. The company's main business activities include the manufacture and sale of pharmaceutical products, cosmetics, and functional foods. Rohto Pharmaceutical's product range spans eye care, including eye drops and lotions; skincare, featuring dermatological preparations, lip balms, and sunscreens; and oral medications, which include digestive medicines and Chinese herbal supplements. Additionally, the company offers extracorporeal test drugs and various other health-related products. The company is headquartered in Osaka, Japan, and its shares are listed on the Tokyo Stock Exchange.